5-HT6receptor antagonists as treatment for age-related cognitive decline

Reviews in the Neurosciences

Volumn 25, Issue 3, 2014, Pages 417-427

  Quiedeville, Anne ^a   Boulouard, Michel ^a   Da Silva Costa Aze, Virginie ^b   Dauphin, François ^a   Bouet, Valentine ^a   Freret, Thomas ^a  

^a UNIVERSITÉ DE CAEN   (France)

^b CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

Ageing; Alzheimer's; Clinical trials; Memory; Plasticity; Serotonin

Indexed keywords

3 PHENYLSULFONYL 8 (1 PIPERAZINYL)QUINOLINE; AVN 322; BAPINEUZUMAB; BEXAROTENE; DIMEBON; DONEPEZIL; GALANTAMINE; MEMANTINE; PF 05212337; RIVASTIGMINE; SEROTONIN 6 ANTAGONIST; TACRINE; UNCLASSIFIED DRUG; SEROTONIN 6 RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

AGING; COGNITIVE DEFECT; DEGENERATIVE DISEASE; EXPERIMENTAL MODEL; HUMAN; LEARNING DISORDER; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; REVIEW; WORKING MEMORY; ANIMAL; ARTICLE; METABOLISM;

AGING; ANIMALS; COGNITION DISORDERS; HUMANS; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 84907172251     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/revneuro-2014-0013     Document Type: Review

References (80)

1. Ahlander M. Misane I. Sch ött P.A. and Ogren S.O. (1999). A behavioral analysis of the spatial learning deficit induced by the NMDA receptor antagonist MK-801 (dizocilpine) in the rat. Neuropsychopharmacology 21 414-426
2. Ansanay H. Dumuis A. Sebben M. Bockaert J. and Fagni L. (1995). cAMP-dependent long-lasting inhibition of a K+ current in mammalian neurons. Proc. Natl. Acad. Sci. USA 92 6635-6639
3. Balmanno K. and Cook S.J. (2009). Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ. 16 368-377
4. Bartus R.T. (2000). On neurodegenerative diseases models and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp. Neurol. 163 495-529
5. Bartus R.T. Dean R.L. 3rd Beer B. and Lippa A.S. (1982). The cholinergic hypothesis of geriatric memory dysfunction. Science 217 408-414
6. Bekinschtein P. Cammarota M. Katche C. Slipczuk L. Rossato J.I. Goldin A. Izquierdo I. and Medina J.H. (2008). BDNF is essential to promote persistence of long-term memory storage. Proc. Natl. Acad. Sci. USA 105 2711-2716
7. Bezprozvanny I . (2010). The rise and fall of Dimebon. Drug News Perspect. 23 518-523
8. Bhaskar K. Yen S.-H. and Lee G. (2005). Disease-related modifications in tau affect the interaction between Fyn and Tau. J. Biol. Chem. 280 35119-35125.
9. Birks J., 2006, Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst. Rev.,(1) Art.No.: CD005593.,doi:10.1002/14651858.CD005593.
10. Bö s M. Sleight A.J. Godel T. Martin J.R. Riemer C. and Stadler H. (2001). 5-HT(6) receptor antagonists: lead optimisation and biological evaluation of N-aryl and N-heteroaryl 4-amino-benzene sulfonamides. Eur. J. Med. Chem. 36 165-178
11. Bourson A. Borroni E. Austin R.H. Monsma F.J. Jr and Sleight A.J. (1995). Determination of the role of the 5-HT6 receptor in the rat brain: a study using antisense oligo nucleotides. J. Pharmacol. Exp. Ther. 274 173-180
12. Callaghan C.K. Hok V. Della-Chiesa A. Virley D.J. Upton N. and O'Mara S.M. (2012). Age-related declines in delayed non-match-to-sample perfo rmance (DNMS) are reversed by the novel 5HT6 receptor antagonist SB742457. Neuropharmacology 63 890-897
13. Codony X. Vela J.M. and Ramí rez M.J. (2011). 5-HT(6) receptor and cognition. Curr. Opin. Pharmacol. 11 94-100
14. Csernansky J.G. Martin M. Shah R. Bertchume A. Colvin J. and Dong H. (2005). Cholinesterase inhibitors ameliorate behavioral deficits induced by MK-801 in mice. Neuropsyc hopharmacology 30 2135-2143
15. Da Silva Costa V. Duchatelle P. Boulouard M. and Dauphin F. (2009). Selective 5-HT6 receptor blockade improves spatial recognition memory and reverses age-related deficit s in spatial recognition memory in the mouse. Neuropsychopharmacology 34 488-500
16. Da Silva Costa-Aze V. Dauphin F. and Boulouard M. (2011). Serotonin 5-HT6 receptor blockade reverses the age-related deficits of recognition memory and working memory in mice. Behav. Brain Res. 222 134-140
17. Da Silva Costa-Aze V. Quiedeville A. Boulouard M. and Dauphin F. (2012). 5-HT6 receptor blockade differentially affect s scopolamine-induced deficits of working memory recognition memory and aversive learning in mice. Psychopharmacology 222 99-115
18. Dawson L.A. Nguyen H.Q. and Li P. (2000). In vivo effects of the 5-HT (6) antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline dopamine 5-HT glutamate and aspartate. Br. J. Pharmacol. 130 23-26
19. Dawson L.A. Nguyen H.Q. and Li P. (2001). The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology 25 662-668
20. De Bruin N.M.W.J. Prickaerts J. van Loevezijn A. Venhorst J. de Groote L. Houba P. Reneerkens O. Akkerman S. and Kruse C.G. (2011). Two novel 5-HT6 receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognit ion and object location tasks in Wistar rats. Neurobiol. Learn. Mem. 96 392-402
21. De Foubert G. Khundakar A.A. and Zetterströ m T.S. (2013). Effects of repeated 5-HT6 receptor stimulation on BDNF gene expression and cell survival. Neurosci. Lett. 553 211-215
22. Foley A.G. Murphy K.J. Hirst W.D. Gallagher H.C. Hagan J.J. Upton N. Walsh F.S. and Regan C.M. (2004). The 5-HT(6) receptor an tagonist SB-271046 reverses scopolaminedisrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats. Neuropsychopharmacology 29 93-100
23. Foley A.G. Hirst W.D. Gallagher H.C. Barry C. Hagan J.J. Upton N. Walsh F.S. Hunter A.J. and Regan C.M. (2008). The selective 5-HT6 receptor antagonists SB-271046 and SB-399885 potentiate N CAM PSA immunolabeling of dentate granule cells but not neurogenesis in the hippocampal formation of mature Wistar rats. Neuropharmacology 54 1166-1174
24. Fone K.C.F. (2008). An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function. Neuropharmacology 55 1015-1022
25. Gallagher M. Stocker A.M. and Koh M.T. (2011). Mindspan: lessons from rat models of neurocognitive aging. ILAR J. 52 32-40
26. Gandy S. and DeKosky S.T. (2013). Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress. Annu. Rev. Med. 64 367-383
27. Garcia-Alloza M. Hirst W.D. Chen C.P.L.-H. Lasheras B. Francis P.T. and Ramírez M.J. (2004). Differential involvement of 5-HT(1B/1D) and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer's disease. Neuropsychopharmacology 29 410-416
28. Gé rard C. el Mestikawy S. Lebrand C. Adrien J. Ruat M. Traiffort E. Hamon M. and Martres M.P. (1996). Quantitative RT-PCR distribution of serotonin 5-HT6 receptor mRNA in the central nervous system of control or 57-dihydroxytryptaminetreated rats. Synapse 23 164-173
29. Gower A.J. and Lamberty Y. (1993). The aged mouse as a model of cognitive decline with special emphasis on studies in NMRI mice. Behav. Brain Res. 57 163-173
30. Gravius A. Laszy J. Pietraszek M. Sághy K. Nagel J. Chambon C. Wegener N. Valastro B. Danysz W. and Gyertyán I. (2011). Effects of 5-HT6 antagonists Ro-4368554 and SB-258585 in tests used for the detection of cognitive enhancement and antipsychotic-like activity. Behav. Pharmacol. 22 122-135.
31. Hasselmo M.E.,Mc Gaughy J., 2004, High acetylcholine levels set circuit dynamics for attention and encoding and low acetylcholine levels set dynamics for consolidation, Prog. Brain Res., 145, 207-231
32. Hirst W.D. Abrahamsen B. Blaney F.E. Calver A.R. Aloj L. Price G.W. and Medhurst A.D. (2003). Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors inves tigated by radioligand binding site-directed mutagenesis and molecular modeling. Mol. Pharmacol. 64 1295-1308
33. Hirst W.D. Stean T.O. Rogers D.C. Sunter D. Pugh P. Moss S.F. Bromidge S.M. Riley G. Smith D.R. Bartlett S. et al. (2006). SB-399885 is a potent selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur. J. Pharmacol. 553 109-119
34. Ivachtchenko A.V. and Ivanenkov Y.A. (2012). 5HT(6) receptor antagonists: a patent update. Part 1. Sulfonyl derivatives. Expert Opin. Ther. Pat. 22 917-964
35. Kendall I. Slotten H.A. Codony X. Burgueño J. Pauwels P.J. Vela J.M. and Fone K.C.F. (2011). E-6801 a 5-HT6 receptor agonist improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission i n the rat. Psychopharmacology (Berl.) 213 413-430
36. King M.V. Sleight A.J. Woolley M.L. Topham I.A. Marsden C.A. and Fone K.C.F. (2004). 5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation-an effect sensitive to NMDA receptor antagonism. Neuropharmacology 47 195-204
37. Kinsey A.M. Wainwright A. Heavens R. Sirinathsinghji D.J. and Oliver K.R. (2001). Distribution of 5-HT(5A) 5-HT(5B) 5-HT(6) and 5-HT(7) receptor mRNAs in the rat brain. Brain Res. Mol. Brain Res. 88 194-198
38. Klinkenberg I. and Blokland A. (2010). The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies. Neurosci. Biobehav. Rev. 34 1307-1350
39. Kohen R. Metcalf M.A. Khan N. Druck T. Huebner K. Lachowicz J.E. Meltzer H.Y. Sibley D.R. Roth B.L. and Hamblin M.W. (1996). Cloning characterization and chromosomal localization of a human 5-HT6 s erotonin receptor. J. Neurochem. 66 47-56
40. Kohen R. Fashingbauer L.A. Heidmann D.E. Guthrie C.R. and Hamblin M.W. (2001). Cloning of the mouse 5-HT6 serotonin receptor and mutagenesis stud ies of the third cytoplasmic loop. Brain Res. Mol. Brain Res. 90 110-117
41. Lezoualc'h F. and Robert S.J. (2003). The serotonin 5-HT4 receptor and the amyloid precursor protein processing. Exp. Gerontol. 38 159-166
42. Lieben C.K.J. Blokland A. Sik A. Sung E. van Nieuwenhuizen P. and Schreiber R. (2005). The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotoner gic models of memory deficiency in the rat. Neuropsychopharmacology 30 2169-2179
43. Lindner M.D. Hodges D.B. Jr Hogan J.B. Orie A.F. Corsa J.A. Barten D.M. Polson C. Robertson B.J. Guss V.L. Gillman K.W. et al. (2003). An assessment of the effects of serotonin 6 (5-HT6) receptor antagonists in rodent models of learning. J. Pharmacol. Exp. Ther. 307 682-691
44. Loiseau F. Deke yne A. and Millan M.J. (2008). Pro-cognitive effects of 5-HT6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex. Psychopharmacology (Berl.) 196 93-104
45. Lork e D.E. Lu G. Cho E. and Yew D.T. (2006). Serotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patients. BMC Neurosci. 7 36
46. Maher-Edwards, G., Dixon, R., Hunter, J., Gold, M., Hopton, G., Jacobs, G., Hunter, J., and Williams, P. (2011). SB-742457 and donepezil in Alzheimer disease: a randomized, placebocontrolled study. Int. J. Geriatr. Psychiatry 26, 536-544.
47. Maher-Edwards G. Dixon R . Hunter J. Gold M. Hopton G. Jacobs G. Hunter J. and Williams P. (2011). SB-742457 and donepezil in Alzheimer disease: a randomized placebocontrolled study. Int. J. Geriatr. Psychiatry 26 536-544. Marcos B. Gil-Bea F.J. Hirst W.D. García-Alloza M. and Ramírez M.J. (2006). Lack of localization of 5-HT6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT6 receptor-me diated acetylcholine release. Eur. J. Neurosci. 24 1299-1306
48. Marcos B. Chuang T.T. Gil-Bea F.J. and Ramirez M.J. (2008a ). Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat. Br. J. Pharmacol. 155 434-440
49. Marcos B. Garcí a-Alloza M. Gil-Bea F.J. Chuang T.T. Francis P.T. Chen C.P. Tsang S.W.T.Y. Lai M.K.P. and Ramírez M.J. (2008b ). Involvement of an altered 5-HT-{6} receptor function in behavioral symptoms of Alzheimer's disease. J. Alzheimers Dis. 14 43-50
50. Martin S.J. Grimwood P.D. and Morris R.G. (2000) . Synaptic plasticity and memory: an evaluation of the hypothesis. Annu. Rev. Neurosci. 23 649-711
51. McShane R. Areosa Sastre A. and Minakaran N. (2006). Memantine for dementia. Cochrane Database Syst. Rev. (2) Art. No.: CD003154. DOI: 10.1002/14651858.CD003154.pub5.
52. Mebratu Y.,Tesfaigzi Y., 2009, How ERK1/2 activation controls cell proliferation and cell death: is subcellular localization the answer? Cell Cycle, 8, 1168-1175.
53. Meffre J. Chaumont-Dubel S. Mannoury la Cour C. Loiseau F. Watson D.J.G. Dekeyne A. Séveno M. Rivet J.-M. Gaven F. Dé léris P. et al. (2012). 5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia. EMBO Mol. Med. 4 1043-1056
54. Meneses A. (20 01). Effects of the 5-HT(6) receptor antagonist Ro 04-6790 on learning consolidation. Behav. Brain Res. 118 107-110
55. Meneses A. Manuel-Apolinar L. Castillo C. and Castillo E. (2007). Memory consolidation and amnesia modify 5-HT6 receptors expression in rat brain: an autoradiographic study. Behav. Brain Res. 178 53-61
56. Mitchell E.S. Hoplight B.J. Lear S.P. and Neumaier J.F. (2006). BGC2 0-761 a novel tryptamine analog enhances memory consolidation and reverses scopolamine-induced memory deficit in social and visuospatial memory tasks through a 5-HT6 receptor-mediated mechanism. Neuropharmacology 50 412-420
57. Mitchell E.S. McDevitt R.A. and Neumaier J.F. (2009). Adaptations in 5-HT receptor expression and function: implications for treatment of cognitive impairment in aging. J. Neurosci. Res. 87 2803-2811
58. Monsma F.J. Jr Shen Y. Ward R.P. Hamblin M.W. and Sibley D.R. (1993). Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol. Pharmacol. 43 320-327
59. Mora F. (2013). Successful brain aging: plasticity environmental enrichment and lifestyle. Dialogues Clin. Neurosci. 15 45-52
60. Neugroschl J. Sano M. (2010). Current treatment and recent clinical research in Alzheimer's disease. MT Sinai J. Med. 77 3-16
61. Oono K. Yoneda T. Manabe T. Yamagishi S. Matsuda S. Hitomi J. Miyata S. Mizuno T. Imaizumi K. Katayama T. e t al. (2004). JAB1 participates in unfolded protein responses by association and dissociation with IRE1. Neurochem. Int. 45 765-772
62. Perez-García G. and Meneses A. (2005). Oral administration of the 5-HT 6 receptor antagonists SB-357134 and SB-399885 improves memory formation in an autoshaping learning task. Pharmacol. Biochem. Behav. 81 673-682
63. Riemer C. Borroni E. Levet-Trafit B. Martin J.R. Poli S. Porter R.H.P. and Bö s M. (2003). Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine a potent and selective 5-HT6 rece ptor antagonist. J. Med. Chem. 46 1273-1276
64. Roberson E.D. Halabisky B. Yoo J.W. Yao J. Chin J. Yan F. Wu T. Hamto P. Devidze N. Yu G.-Q. et al. (2011). Amyloid-?/Fyn-induced synaptic network and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J. Neurosci. 31 700-711
65. Ruat M. Traiffort E. Arrang J.M. Tardivel-Lacombe J. Diaz J. Leurs R. and Schwartz J.C. (1993). A novel rat serotonin (5-HT6) receptor: molecular cloning localization and stimulation of cAMP accumulat ion. Biochem. Biophys. Res. Commun. 193 268-276
66. Schreiber R. Vivian J. Hedley L. Szczepanski K. Secchi R.L. Zuzow M. van Laarhoven S. Moreau J.-L. Martin J.R. Sik A. et al. (2007). Effects of the novel 5-HT(6) receptor antagonist RO4368554 in rat models for cognition and sensorimotor gating. Eur. Neuropsychopharmacol. 17 277-288
67. Selkoe D.J. (2002). Alzheimerń s disease is a synaptic failure. Science 298 789-791
68. Shirazi-Southall S. Rodriguez D.E. and Nomikos G.G. (2002). Effects of typical and atypical antipsychotics and receptor selective compounds on ace tylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 26 583-594
69. Ska B. and Joanette Y. (2006). Normal aging and cognition. Med. Sci. (Paris) 22 284-287
70. Tass one A. Madeo G. Sciamanna G. Pisani A. and Bonsi P. (2010). Electrophysiology of 5-HT6 receptors. Int. Rev. Neurobiol. 94 111-128
71. Van der Staay F.J. (2006). Animal models of behavioral dysfunctions: basic concepts and classifications and an evaluation strategy. Brain Res. Rev. 52 131-159
72. Ward R.P. and Dorsa D.M. (1996). Colocalization of serotonin receptor subtypes 5-HT2A 5-HT2C and 5-HT6 with neuropeptides in rat striatum. J. Comp. Neurol. 370 405-414.
73. West P.J.,Marcy V.R.,Marino M.J.,Schaffhauser H., 2009, Activation of the 5-HT(6) receptor attenuates long-term potentiation and facilitates GABAergic neurotransmission in rat hippocampus, Neuroscience, 164, 692-701.
74. Woods S. Clarke N.N. Layfield R. and Fone K.C.F. (2012). 5-HT(6) receptor agonists and antagonists enhance learning and memory in a conditioned emotion response paradigm by modulation of cholinergic and glutamatergic mechanisms. Br. J. Pharmacol. 167 436-449
75. Woolley M.L. Marsden C.A. Sleight A.J. and Fone K.C.F. (2003). Reversal of a cholinergic-induced deficit in a rodent model of recognition memory by the selective 5-HT6 receptor antagonist Ro 04-6790. Psychopharmacology (Berl. ) 170 358-367
76. Yoshioka M. Matsumoto M. Togashi H. and Mori K. (1998). Central distribution and function of 5-HT6 receptor subtype in the rat brain. Ann. NY Acad. Sci. 861 244
77. Yun H.-M. and Rhim H. (2011). The serotonin-6 receptor as a novel therapeutic target. Exp. Neurobiol. 20 159-168
78. Yun H.-M. Kim S. Kim H.-J. Kostenis E. Kim J.I. Seong J.Y. Baik J.-H. and Rhim H. (2007). The novel cellular mechanism of human 5-HT6 receptor through an interaction with Fyn. J. Biol. Chem. 282 5496-5505
79. Yun H.-M. Baik J.-H. Kang I. Jin C. and Rhim H. (2010). Physical interaction of Jab1 with human serotonin 6 G-protein-coupled receptor and their possible roles in cell survival. J. Biol. Chem. 285 10016-10029
80. Zhang M.-Y. Hughes Z.A. Kerns E.H . Lin Q. and Beyer C.E. (2007). Development of a liquid chromatography/tandem mass spectrometry method for the quantitation of acetylcholine and related neurotransmitters in brain microdialysis samples. J. Pharm. Biomed. Anal. 44 586-593